Results 151 to 160 of about 786,314 (373)

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

Frontiers in Pharmacology
BackgroundTeprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post ...
Jiawei Zhao, Yong Tao
doaj   +1 more source

Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 [PDF]

, 2004
Elizabeth Begier, Dale R. Burwen, Penina Haber, Robert Ball   +3 more
openalex   +1 more source

Analysis of CFSAN Adverse Event Reporting System and Twitter

, 2019
For the public health monitoring, FDA is releasing the public data for consumer complaint data. This CARES database contains information on product complaint reports submitted to FDA. It includes dietary supplements and food adversary incidents. Also, the FDA is trying to utilize SNS data like Twitter as real-time monitoring tools. In this analysis, we
openaire   +1 more source

Quantitative Assessment of Upper Limb Ataxia Using a Virtual Reality‐Based Evaluation System

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebellar ataxia impairs coordination and balance, reducing quality of life. Conventional clinical scales, including the Scale for the Assessment and Rating of Ataxia (SARA) and the International Cooperative Ataxia Rating Scale (ICARS), are widely used to assess ataxia but are limited by subjectivity and inter‐rater variability ...
Masayuki Sato, Takayuki Abe, Sho Aoki, Setsuki Tsukagoshi, Yasushi Yuminaka, Yoshio Ikeda   +5 more
wiley   +1 more source

Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system

Frontiers in Pharmacology
Background: Anti-Calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) have shown significant efficacy in preventing migraine. However, there have been limited reports of adverse events (AEs) after marketing, particularly for eptinezumab
Wenfang Sun, Yali Li, Binbin Xia, Jing Chen, Yang Liu, Jingyao Pang, Fang Liu, Hua Cheng   +7 more
doaj   +1 more source

Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review

Arthritis Care &Research, EarlyView.
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox, Saeed Farooq, Helen Twohig, Ian C. Scott   +3 more
wiley   +1 more source

Recommended immunization schedules for persons aged 0 through 18 years -- United States, 2016 [PDF]

This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible.

core  

Effect of Nonsteroidal Anti‐Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective Imaging evidence of active sacroiliitis is important for diagnosis, classification, and monitoring of axial spondyloarthritis (axSpA). However, there is no consistent guidance on whether patients should temporarily stop nonsteroidal anti‐inflammatory drugs (NSAIDs) before magnetic resonance imaging (MRI).
Gareth T. Jones, Alexander N. Bennett, Raj Sengupta, Pedro M. Machado, Helena Marzo‐Ortega, Lorna Aucott, Margaret A. Hall‐Craggs, Timothy J. P. Bray, Alan Bainbridge, Ruaridh M. Gollifer, Gary J. Macfarlane   +10 more
wiley   +1 more source

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system

Frontiers in Oncology
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang, Hewen Chen, Yuying Zhou, Jianfeng Chen, Jiwei Cao   +4 more
doaj   +1 more source

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations [PDF]

, 2011
Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno   +2 more
openalex   +1 more source